ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Clinical trial NCT00272987 · TERMINATED

Trial details

NCT number: NCT00272987
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Neoplasms, Breast

Start date: 2005-12-13
Primary completion: 2009-07-31
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.